Literature DB >> 33925055

Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort.

Muneerah Smith1, Houari B Abdesselem2,3, Michelle Mullins1, Ti-Myen Tan4, Andrew J M Nel1, Maryam A Y Al-Nesf5, Ilham Bensmail2, Nour K Majbour2, Nishant N Vaikath2, Adviti Naik2, Khalid Ouararhni2, Vidya Mohamed-Ali6, Mohammed Al-Maadheed6, Darien T Schell1, Seanantha S Baros-Steyl1, Nur D Anuar4, Nur H Ismail4, Priscilla E Morris4, Raja N R Mamat4, Nurul S M Rosli4, Arif Anwar4, Kavithambigai Ellan7, Rozainanee M Zain7, Wendy A Burgers8,9,10, Elizabeth S Mayne11, Omar M A El-Agnaf2, Jonathan M Blackburn1,4,10.   

Abstract

The COVID-19 pandemic has affected all individuals across the globe in some way. Despite large numbers of reported seroprevalence studies, there remains a limited understanding of how the magnitude and epitope utilization of the humoral immune response to SARS-CoV-2 viral anti-gens varies within populations following natural infection. Here, we designed a quantitative, multi-epitope protein microarray comprising various nucleocapsid protein structural motifs, including two structural domains and three intrinsically disordered regions. Quantitative data from the microarray provided complete differentiation between cases and pre-pandemic controls (100% sensitivity and specificity) in a case-control cohort (n = 100). We then assessed the influence of disease severity, age, and ethnicity on the strength and breadth of the humoral response in a multi-ethnic cohort (n = 138). As expected, patients with severe disease showed significantly higher antibody titers and interestingly also had significantly broader epitope coverage. A significant increase in antibody titer and epitope coverage was observed with increasing age, in both mild and severe disease, which is promising for vaccine efficacy in older individuals. Additionally, we observed significant differences in the breadth and strength of the humoral immune response in relation to ethnicity, which may reflect differences in genetic and lifestyle factors. Furthermore, our data enabled localization of the immuno-dominant epitope to the C-terminal structural domain of the viral nucleocapsid protein in two independent cohorts. Overall, we have designed, validated, and tested an advanced serological assay that enables accurate quantitation of the humoral response post natural infection and that has revealed unexpected differences in the magnitude and epitope utilization within a population.

Entities:  

Keywords:  SARS-CoV-2 antibodies; SARS-CoV-2 nucleocapsid protein; epitope coverage; humoral response; immunoassay; protein microarray; quantitative antibody binding

Year:  2021        PMID: 33925055     DOI: 10.3390/v13050786

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  5 in total

1.  SARS-CoV-2 herd immunity of the Kyrgyz population in 2021.

Authors:  Anna Y Popova; Omor T Kasymov; Vyacheslav Y Smolenski; Vyacheslav S Smirnov; Svetlana A Egorova; Zuridin S Nurmatov; Anzhelika M Milichkina; Gulmira S Suranbaeva; Tatiana E Kuchuk; Irina V Khamitova; Elena V Zueva; Valery A Ivanov; Zhanylai N Nuridinova; Aisuluu A Derkenbaeva; Victoria G Drobyshevskaya; Gulsun Z Sattarova; Marat T Kaliev; Alexandra V Gubanova; Oyuna B Zhimbaeva; Alexandra P Razumovskaya; Vyacheslav N Verbov; Ivan V Likhachev; Alexey V Krasnov; Areg A Totolian
Journal:  Med Microbiol Immunol       Date:  2022-07-02       Impact factor: 4.148

2.  Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination.

Authors:  Oya Ozlem Eren-Kutsoylu; Ozgur Appak; Arzu Nazli-Zeka; Gokcen Omeroglu-Simsek; Nil Tekin; Basak Bayram; Ayca Arzu Sayiner; Nesim Tanglay; Vildan Avkan-Oguz
Journal:  Ir J Med Sci       Date:  2022-07-12       Impact factor: 2.089

3.  Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).

Authors:  Khadija Khan; Gila Lustig; Mallory Bernstein; Derseree Archary; Sandile Cele; Farina Karim; Muneerah Smith; Yashica Ganga; Zesuliwe Jule; Kajal Reedoy; Yoliswa Miya; Ntombifuthi Mthabela; Nombulelo P Magula; Richard Lessells; Tulio de Oliveira; Bernadett I Gosnell; Salim Abdool Karim; Nigel Garrett; Willem Hanekom; Linda-Gail Bekker; Glenda Gray; Jonathan M Blackburn; Mahomed-Yunus S Moosa; Alex Sigal
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

4.  Ethnicity-Specific Features of COVID-19 Among Arabs, Africans, South Asians, East Asians, and Caucasians in the United Arab Emirates.

Authors:  Fatmah Al Zahmi; Tetiana Habuza; Rasha Awawdeh; Hossam Elshekhali; Martin Lee; Nassim Salamin; Ruhina Sajid; Dhanya Kiran; Sanjay Nihalani; Darya Smetanina; Tatsiana Talako; Klaus Neidl-Van Gorkom; Nazar Zaki; Tom Loney; Yauhen Statsenko
Journal:  Front Cell Infect Microbiol       Date:  2022-03-16       Impact factor: 5.293

Review 5.  A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action.

Authors:  Seanantha S Baros-Steyl; Saba Al Heialy; Ahlam H Semreen; Mohammad H Semreen; Jonathan M Blackburn; Nelson C Soares
Journal:  Proteomics       Date:  2022-07-15       Impact factor: 5.393

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.